NAFLD patients who experienced SARS-Cov-2 infection had higher levels of ACE2 compared to those who did not have the infection (3.24 ± 1.49 vs. 1.49 ± 1.32, p = 0.0320; Supplementary Figure S1c). This evidence concerns the gene ACE2 and metabolic dysfunction-associated steatotic liver disease.